Annual Drug Patent Expirations for JANUVIA
Januvia is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for JANUVIA.
This drug has one hundred and seventeen patent family members in forty-six countries.
The generic ingredient in JANUVIA is sitagliptin phosphate. Three suppliers are listed for this compound. Additional details are available on the sitagliptin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
